~~<i id='1B11386B48'><strike id='1B11386B48'><tt id='1B11386B48'><pre id='1B11386B48'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

author：comprehensive 2025-09-30 00:51:24 - browse：63

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Maker of FluMist seeks to allow at

focus

leisure time

hotspot

knowledge

leisure time

entertainment

Wanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyourinb

WSS

The haunting brain science of long Covid

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Will the FTC rein in IQVIA's health data empire?

Dems pitch expanding Medicare power to negotiate drug prices

Dems pitch expanding Medicare power to negotiate drug prices

explore

explore

focus

Apple is now the first public company to be valued at $3 trillion

Roche’s Alnylam deal shows drug firms interested in heart drugs

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Drug repurposing or repositioning? The language matters

What causes rare myocarditis in young men after Covid vaccines?

Apple is now the first public company to be valued at $3 trillion

Eli Lilly to pay $200M for Beam’s stake in gene

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

UHS says company favors patients whose insurance pays more

leisure time

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Biogen says it will cut costs by $700 million, slash 1,000 jobs

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

Dems pitch expanding Medicare power to negotiate drug prices

Rise in cancer among younger people worries and puzzles doctors

Biden warns of ‘dark winter’ during final presidental debate

hotspot

knowledge

leisure time

entertainment